acetoacetic acid has been researched along with Liver Neoplasms in 10 studies
acetoacetic acid : A 3-oxo monocarboxylic acid that is butyric acid bearing a 3-oxo substituent.
Liver Neoplasms: Tumors or cancer of the LIVER.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Sorafenib is a first-line drug for advanced-stage HCC patients." | 1.72 | HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells. ( Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY, 2022) |
| "Primary liver cancer is the fifth leading death of cancers in men, and hepatocellular carcinoma (HCC) accounts for approximately 90% of all primary liver cancer cases." | 1.72 | HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells. ( Chen, TL; Chien, CY; Chiu, WC; Liao, YJ; Suk, FM; Wu, CY, 2022) |
| "Morris hepatoma 7777 cells freshly isolated from highly malignant tumors grown in the hindlimb of buffalo rats actively convert ketone bodies to cholesterol and fatty acids." | 1.29 | Utilization and preferred metabolic pathway of ketone bodies for lipid synthesis by isolated rat hepatoma cells. ( Elson, C; Hildebrandt, LA; Shrago, E; Spennetta, T, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 3 (30.00) | 18.7374 |
| 1990's | 4 (40.00) | 18.2507 |
| 2000's | 1 (10.00) | 29.6817 |
| 2010's | 1 (10.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Suk, FM | 3 |
| Wu, CY | 3 |
| Chiu, WC | 3 |
| Chien, CY | 3 |
| Chen, TL | 3 |
| Liao, YJ | 3 |
| Wang, MR | 1 |
| Zhang, X | 1 |
| Liu, YQ | 1 |
| Uehara, Y | 1 |
| Engel, T | 1 |
| Li, Z | 1 |
| Goepfert, C | 1 |
| Rust, S | 1 |
| Zhou, X | 1 |
| Langer, C | 1 |
| Schachtrup, C | 1 |
| Wiekowski, J | 1 |
| Lorkowski, S | 1 |
| Assmann, G | 1 |
| von Eckardstein, A | 1 |
| BROWN, GW | 1 |
| CHAIKOFF, IL | 1 |
| CHAPMAN, DD | 1 |
| Tani, T | 2 |
| Taki, Y | 2 |
| Aoyama, H | 1 |
| Jikkoh, A | 1 |
| Arii, S | 1 |
| Ozawa, K | 4 |
| Tobe, T | 2 |
| Hildebrandt, LA | 1 |
| Spennetta, T | 1 |
| Elson, C | 1 |
| Shrago, E | 1 |
| Kajimura, K | 1 |
| Moriyasu, F | 1 |
| Someda, H | 1 |
| Okuma, M | 1 |
| Mori, K | 2 |
| Higashi, S | 1 |
| Tabata, N | 1 |
| Kondo, KH | 1 |
| Kai, M | 1 |
| Miyamoto, K | 1 |
| Maeda, Y | 1 |
| Setoguchi, T | 1 |
| Iwata, S | 1 |
| Shimahara, Y | 1 |
| Kobayashi, N | 1 |
| Kumada, K | 1 |
| Yamaoka, Y | 1 |
| Jikko, A | 1 |
| Minematsu, S | 1 |
| Yamamoto, M | 1 |
| Kamiyama, Y | 1 |
10 other studies available for acetoacetic acid and Liver Neoplasms
| Article | Year |
|---|---|
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
HMGCS2 Mediation of Ketone Levels Affects Sorafenib Treatment Efficacy in Liver Cancer Cells.
Topics: Antineoplastic Agents; Carcinoma, Hepatocellular; Extracellular Signal-Regulated MAP Kinases; Humans | 2022 |
[Acetoacetate extract from Celastrus orbiculatus Thunb inhibits growth of RFP-xenografted human liver carcinoma].
Topics: Acetoacetates; Animals; Carcinoma, Hepatocellular; Celastrus; Female; Hep G2 Cells; Humans; Liver Ne | 2012 |
Polyunsaturated fatty acids and acetoacetate downregulate the expression of the ATP-binding cassette transporter A1.
Topics: Acetoacetates; Animals; Carcinoma, Hepatocellular; Cholesterol, HDL; Diabetes Mellitus, Experimental | 2002 |
Demonstration of beta-oxidation and acetoacetate formation in a mouse hepatoma.
Topics: Acetoacetates; Animals; Carcinoma, Hepatocellular; Liver Neoplasms; Liver Neoplasms, Experimental; M | 1953 |
Changes in acetoacetate/beta-hydroxybutyrate ratio in arterial blood following hepatic artery embolization in man.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeu | 1984 |
Utilization and preferred metabolic pathway of ketone bodies for lipid synthesis by isolated rat hepatoma cells.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Animals; Carcinoma, Hepatocellular; Cell Separation; Citrates; | 1995 |
Transcatheter hepatic arterial drug infusion therapy for hepatocellular carcinoma. Effect on the arterial ketone body ratio.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Aged; Antineoplastic Agents; Butyrates; Carcinoma, Hepatocellu | 1993 |
A predominant increase of arterial beta-hydroxybutyrate concentration during partial hepatectomies in patients with impaired indocyanine green clearance test.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Coloring Agents; Female; Hepatectomy; Hepatic Veins; Humans; I | 1999 |
Diurnal fluctuations of arterial ketone body ratio in normal subjects and patients with liver dysfunction.
Topics: Acetoacetates; Adult; Aged; Blood Glucose; Carcinoma, Hepatocellular; Chronic Disease; Circadian Rhy | 1991 |
Short-term changes in blood ketone body ratios in the phase immediately after hepatic artery embolization: their clinical significance.
Topics: 3-Hydroxybutyric Acid; Acetoacetates; Adult; Aged; Carcinoma, Hepatocellular; Embolization, Therapeu | 1986 |